# Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment

> **NCT04435964** · — · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 247 (actual)

## Conditions studied

- Melanoma
- Lung Cancer
- Head and Neck Cancer
- Urogenital Neoplasms
- Breast Cancer

## Interventions

- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT04435964
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-25
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04435964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04435964, "Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04435964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*